Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Stavropoulos

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Journal of Neurology|March 1, 1996
Hereditary neuropathy with liability to pressure palsies: the same molecular defect can result in diverse clinical presentationE Andreadou, C Yapijakis, G P Paraskevas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Journal of Neurology|March 1, 1996
Hereditary neuropathy with liability to pressure palsies: the same molecular defect can result in diverse clinical presentationE Andreadou, C Yapijakis, G P Paraskevas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
The British Journal of Dermatology|May 4, 2021
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE studyD F Murrell, A Patsatsi, P Stavropoulos, et al.
Pageof 4